Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026
05/08/2026 13:18
BRIEF-Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026 Aug 5 (Reuters) - BioCryst Pharmaceuticals, Inc. BCRX.O:
BIOCRYST PHARMACEUTICALS Q2 EPS USD 0.3
BIOCRYST PHARMACEUTICALS OUTLOOK FY SALES USD 690-715 MILLION
BIOCRYST PHARMACEUTICALS, - CASH, CASH EQUIVALENTS, RESTRICTED CASH AND INVESTMENTS $354 MILLION AT JUNE 30, 2026
Source text: ID:nGNX7XG5N9
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026